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Introduction and epidemiology
Trauma is the leading cause of mortality for persons 
between one and 44 years of age. Despite advances 
in transfusion practices and improvements in 
the prehospital management of trauma patients, 
bleeding remains the leading cause of death.1,2 
Twenty-five percent of severe trauma cases involve 
a major bleed associated with impaired blood 
clotting following trauma-induced coagulopathy 
(TIC). Such TIC contributes significantly to 
bleeding and is an independent factor of poor 
prognosis. It may occur very early after injury6 and 
is associated with increases in: the risk of death 
during the first 24 hours, transfusion requirements, 
hospital stays and other complications.3-5 
This chapter aims to review the mechanisms 
and treatment of TIC, as well as the practical 
implications of TIC for surgical management. The 
role of laboratory testing in the management of TIC 
is also addressed.
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Abstract. Facing coagulation disorders after acute trauma. Problems/objectives: Trauma is the leading cause of 
mortality for persons between one and 44 years of age, essentially due to bleeding complications. 
Methodology: We screened the PubMed, Scopus and Cochrane Library databases, using specific keywords. Only 
publications in English were considered.
Main results: The pathophysiology of trauma-induced coagulopathy (TIC) is complex and includes the classic “lethal 
triad” (i.e., haemodilution, acidosis, hypothermia) but may also include activation of protein C, endothelial and platelet 
dysfunction, and fibrinogen depletion.
The time between trauma and treatment of the resultant massive bleeding should be as short as possible 
using techniques for rapid control of bleeding and avoiding aggravating factors (hypothermia, metabolic 
acidosis and hypocalcaemia). If given within three hours of injury, tranexamic acid (TXA) reduces all causes 
of mortality in trauma patients and reduces transfusion requirements. In a bleeding patient, crystalloids are 
preferred to colloids and the ratio of fresh frozen plasma to packed red blood cells should be at least 1:2. 
Damage control surgery (DCS) should be considered for patients who present with, or are at risk for developing, the “lethal 
triad”, multiple life-threatening injuries or shock, and in mass casualty situations. DCS can also aid in the evaluation of 
the extent of tissue injuries and the control of haemorrhage and infection. Finally, there is currently no evidence of the 
added value of laboratory assays in the management of TIC.
Conclusions: TIC appears quickly after trauma and should be anticipated and detected as soon as possible. TXA plays a 
central role in the management of such patients. Each institution should establish a local algorithm for the management 
of bleeding patients.
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fibrin polymerization.12 However, unlike the use 
of crystalloids, colloid administration in trauma 
patients is not associated with increased mortality.13 
Nevertheless, it appears that haemodilution is a 
contributor to TIC, rather than its primary cause.
Acidosis and hypothermia are two other 
independent contributors to the coagulopathy 
observed in trauma patients. They impair thrombin 
generation via distinct mechanisms.14 
A body temperature below 34 ºC directly affects 
blood coagulation. In trauma patients, hypothermia 
increases the risk of severe bleeding and represents 
an independent risk factor for mortality.15,16 The 
major adverse effects of hypothermia on coagulation 
are prolonged prothrombin and activated partial 
thromboplastin times.16,17 It leads to platelet 
dysfunction, impairs or inhibits coagulation factor 
activities and increases fibrinolysis.17,18 In models of 
severe hypothermia (< 32 °C), fibrinogen synthesis 
is decreased but fibrinolysis is not increased.14 
Acidosis, induced by tissue hypoperfusion 
followed by a shift to anaerobic metabolism, can be 
worsened by the administration of large amounts of 
Ringer’s lactate solution during early resuscitation. 
It represents an independent predictive factor of 
bleeding and death. Acidosis leads to the impaired 
activity of protease coagulation factors and a 
depletion in fibrinogen storage and platelet count, 
thus compromising clot formation. The rate of 
maximal clot strength on thromboelastography 
is slower, showing a delay in competent clot 
formation.19 Moreover, acidosis leads to prolonged 
clotting times and increased bleeding time.14,20 
Acidosis is also associated with accelerated 
fibrinogen consumption and, while it does not affect 
fibrin formation, it is associated with accelerated 
fibrinolysis.21 
Taken together, acidosis and hypothermia have 
a synergistic effect on the impairment of blood 
coagulation.15 
1.1. Platelet dysfunction in TIC
Platelets play two critical roles in the haemostasis 
process: adhesion and aggregation. At the site of 
endothelial injury, platelets form a haemostatic 
plug and platelets enhance activation of coagulation 
proteases, leading to thrombus formation. Despite 
their pivotal role in early coagulation, assessments 
of platelet function are rarely available in routine 
practice for the early management of trauma.
Methodology
We reviewed the literature by screening the 
PubMed, Scopus and Cochrane Library databases 
using a literature search strategy employing the 
following specific keywords: trauma, trauma-
induced coagulopathy, coagulopathy, bleeding, 
mortality, mechanisms, treatment, tranexamic acid, 
damage control surgery, extracorporeal membrane 
oxygenation. Only publications in English were 
considered.
Part I: Molecular and clinical mechanisms of 
traumatic coagulopathy
In the past, TIC was explained by reference 
to a “lethal triad”: haemodilution, acidosis 
and hypothermia. However, it appears that the 
pathophysiology of TIC is more complex than 
this account permits. In addition to the “lethal 
triad”, TIC also involves activation of protein C, 
endothelial dysfunction, platelet dysfunction and 
fibrinogen depletion.
1. The classic lethal triad
For many years, haemodilution, hypothermia and 
acidosis were considered to be the primary aetiology 
of TIC. It now seems that these conditions should 
rather be considered as precipitating factors of TIC.
In the past, administration of high volumes 
of crystalloid solutions was considered a crucial 
step in trauma resuscitation to stabilize patients’ 
haemodynamic parameters. However, it now 
appears that prehospital crystalloid administration 
worsens coagulopathy, acidaemia and hypothermia, 
affecting thrombin production, a central factor for 
clot formation. The induced dilution coagulopathy 
is directly correlated with the volume of fluid 
administered.7-9 Crystalloid administration acts 
only through this dilution effect. It does not affect 
fibrinogen metabolism.10 Gelatin derivatives also 
act through dilution but have some effects on the 
clot characteristics: decreasing clot weight and clot 
elasticity.11 Solutions derived from hydroxyethyl 
starches cause coagulation factor dilution, a von 
Willebrand-like syndrome, hypocalcaemia, platelet 
coating, an antagonistic effect on the platelet 
fibrinogen receptor GIIb/IIIa and impairment of 
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system but did not aggravate TIC.35 However, a 
recent review shows that hypothermia-associated 
coagulopathy is to a greater extent related to a 
reduced availability of platelet activators than to an 
intrinsic platelet dysfunction.36  
1.2. Endothelial dysfunction in TIC
During trauma, inflammation, cytokine production, 
hypoperfusion, hypoxia-reperfusion injuries or 
sympathoadrenal activation can upset endothelial 
homeostasis. These factors also promote shedding 
of the glycocalyx layer, inducing an auto-
heparinization of the patient that occurs while large 
amounts of anticoagulant glycocalyx components, 
such as syndecan-1 and heparan sulphate, appear in 
the patient’s blood circulation.37-40 High circulating 
levels of syndecan-1 are associated with increased 
mortality.40 Moreover, patients with high levels of 
syndecan-1 show a progressive depletion of protein 
C, increased soluble thrombomodulin expression
and hyperfibrinolysis.40 The trauma-induced de-
granulation of Weibel-Palade bodies enhances en-
dothelial dysfunction and coagulopathy. Weibel-
Palade bodies contain tissue plasminogen activa-
tor (TPA), von Willebrand factor antigen, throm-
bomodulin and angiopoietin-2. These compounds 
promote inflammation, fibrinolysis and vascular 
permeability, leading to interstitial oedema.
1.3. Activated protein c in TIC
Under normal physiological conditions, activated 
protein C (APC) has both cytoprotective and anti-
coagulant effects. It exerts these protective effects 
through activation by the thrombin-thrombomo-
dulin complex in the presence of the endothelial 
protein C receptor. APC prevents thrombin gene-
ration by inhibiting factor Va and factor VIIIa. 
It also demonstrates profibrinolytic activity via 
inhibition of tPA-1. However, in trauma, the gly-
cocalyx shedding and the damaged endothelium
enhance the release of thrombomodulin and 
endothelial protein C receptor in the systemic 
circulation. This crucial step allows for a “thrombin 
switch” to occur, whereby thrombin acts as
an anticoagulant. Indeed, the formation of the
thrombin-thrombomodulin complex (thrombomo-
dulin-thrombin-activated protein C receptor) in the 
systemic circulation leads to the formation of a large 
amount of APC, which can realize the following 
anticoagulant and profibrinolytic activities:41 
The following considerations are important to 
the understanding of the role of platelets in trauma.
1.1.1. Platelet count
On admission, platelet counts in critically injured 
trauma patients are often normal. However, they 
can quickly decrease after admission. Low platelet 
counts at admission and during the course of trauma 
care are associated with increased mortality and 
morbidity.22-24 
1.1.2. Platelet dysfunction
Persistent bleeding despite a platelet count greater 
than 100x109/L without clotting factor deficiency 
indicates the presence of a trauma-induced 
platelet dysfunction. A deficiency of platelet 
aggregation in response to adenosine diphosphate 
(ADP), arachidonic acid, collagen or thrombin 
receptor-activating peptide is often seen in trauma 
patients.23,25-27 The most severe impairments of 
platelet function are observed in brain-injured 
patients.28
Platelet hypofunction on admission of a trauma 
patient to an intensive care unit (ICU) is associated 
with a 10-fold increase in risk of mechanical 
ventilation requirements, lower admission Glasgow 
Coma Scale and a higher level of early mortality.27
A leading cause of trauma-induced platelet 
dysfunction is exposure to high concentrations 
of the platelet activators tissue factor (TF) and 
platelet activating factor (PAF).29 These two 
mediators can activate platelets and subsequently 
render them atomic. The atomic platelets limit 
thrombin production and clot stabilization. Platelet 
receptor inhibition prevents cellular initiation and 
amplification of the clotting cascade, limiting 
thrombin incorporation and clot stabilization, 
which usually stops haemorrhaging.30,31 
1.1.3. Hypothermia
The effect of hypothermia on platelet function 
is not fully understood and published studies 
show conflicting results.32 Hypothermia is 
frequent in trauma patients. It decreases platelet 
adhesion, coagulation factor activities and platelet 
activation.33,34 In a study on pigs, animals with 
mild hypothermia (34 °C) displayed significantly 
longer clotting times and clot formation times, but 
the maximum clot firmness was not significantly 
different from that in normothermia. In this 
study, mild hypothermia affected the coagulation 
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1. Minimize elapsed time
The earlier and more targeted the treatment of 
TIC, the better the results. It is very important to 
reduce the time between admission and control 
of haemorrhagic shock. An initial assessment – 
comprising evaluation of severity, localization 
and the mechanism of trauma, and assessment 
of the patient’s physiological presentation and 
response to resuscitation – facilitates early surgical 
bleeding control. If the source of bleeding is 
unidentified, imaging such as focused assessment 
with sonography for trauma (FAST) or a computed 
tomography (CT) scan should be performed. Various 
tools can assist clinicians’ decision-making, such as 
the Advanced Trauma Life Support classification 
(ATLS) and the Shock Index (heart rate divided by 
systolic blood pressure).48
Reduce the time between trauma and the treatment 
of massive bleeding, consider urgent surgical 
bleeding control (Grade 1A)49
2. Rapid bleeding control techniques
Use of techniques for rapid control of bleeding, 
such as tourniquets on arrival for open extremity 
injuries, may decrease transfusion requirements. 
However, such techniques may themselves cause 
complications (e.g., nerve paralysis or limb 
ischaemia). Damage control surgery (see part III) 
should be initiated as quickly as possible. Topical 
haemostatic agents can be used as adjuncts to 
surgery to obtain haemorrhagic control.
Use rapid bleeding control techniques: tourniquets, 
damage control surgery (Grade 1B)49
- Cleavage of factor Va and factor VIIIa, 
preventing thrombin formation and clot 
stabilization. 
- Activation of APC-related pathways 
associated with the depletion of factors I, II, V, VII, 
VIII, IX and X.
- Inhibition of the physiological inhibitor 
of tissue-derived and urokinase plasminogen 
activators.
These findings are supported by clinical studies 
showing that an increased production of APC in 
patients in the early phase of trauma resuscitation is a 
predictor of coagulopathy and higher mortality.9,42-44 
1.4. Fibrinogen depletion in TIC
Recent studies suggest that a low fibrinogen level 
at admission is correlated with higher mortality in 
trauma patients.41,45
During acute traumatic coagulopathy, fibrinogen 
levels fall quickly after the beginning of major and 
severe bleeding events.45 This is probably the first 
haemostatic abnormality observed in trauma. Loss 
of fibrinogen results from the operation of several 
mechanisms. Firstly, potent and rapid fibrinogen 
consumption is associated with uncontrolled 
bleeding. Secondly, fibrinogen synthesis is 
impaired. Fluid administration leads to a dilution of 
coagulation factors and consequently to fibrinogen 
concentration. Colloids (hydroxyethyl starches and 
gelatins) and hypothermia directly impair fibrin 
polymerization.10,12 Thirdly, the hyperfibrinolysis 
state may cause loss of fibrinogen. The simultaneous 
release of tissue plasminogen activator (TPA) and 
its antagonist, plasminogen activator inhibitor type 
1 (PAI-1), accompany activation of the coagulation 
cascade by exposure of the sub-endothelial surfaces 
and the presence of TF in the systemic circulation. 
During the early phase of trauma, it seems that 
the TPA level outstrips levels of PAI-1, inducing 
a profibrinolytic state.46 These observations 
support the use of antifibrinolytic drugs in trauma 
resuscitation.47 Moreover, APC mediates enhanced 
fibrinolysis through its actions on PAI-1 and TPA.41 
Part II: Medical treatment of trauma-induced 
coagulopathy
This material is summarized in Figure 1.
Figure 1
Treatment of acute traumatic coagulopathy
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3.3. Hypocalcaemia
Low ionized calcium concentrations at admission 
are associated with an increase in mortality as well 
as a need for massive transfusion. The normal range 
for ionized calcium is between 1.1 and 1.3 mmol/L 
and is inversely correlated with blood pH. Citrate 
used in blood products (fresh frozen plasma and 
platelets) exerts its anticoagulant effect by binding 
ionized calcium.
Calcium levels should be monitored and maintained 
in the normal range during massive transfusions 
(Grade 1C)49
4. Antifibrinolytics 
Tranexamic acid (TXA) reduces all causes of 
mortality in trauma patients and reduces transfusion 
requirements (CRASH-2 trial).47 The risk of death 
due to bleeding is significantly decreased if TXA 
is given within one hour of trauma injury and 
this beneficial effect persists for administration 
up to three hours after injury. However, TXA 
administration more than three hours after trauma 
leads to an increased risk of death due to bleeding.54 
The ongoing CRASH-3 trial will evaluate TXA for 
the treatment of significant TBI in term of death 
and disability.55 In addition, TXA does not increase 
the risk of vascular occlusive events.56
Give TXA as a 1g bolus over 10 minutes as early as 
possible, followed by another 1g given continuously 
over the next eight hours49 (Grade 1A)
5. Fluids 
The use of fluids as volume replacement therapy in 
hypotensive patients should be undertaken carefully, 
taking into account the type and amount of fluid 
given to the patient. The goal of fluid replacement 
therapy is to restore tissue perfusion to maintain 
aerobic cell function. The optimal type of fluid is 
still a matter of debate. It seems that administration 
of crystalloids during the initial treatment of a 
hypotensive bleeding patient is justified. Ringer’s 
lactate solution should be avoided in TBI due to 
the risk of fluid shifting into the damaged cerebral 
tissue. After this initial infusion, colloids might be 
considered to replace fluid loss. Older hydroxyethyl 
starch (HES) solutions with higher molecular weight 
3. Avoid aggravating factors 
Three factors aggravate coagulation disorders: 
hypothermia (temperature < 35 °C), metabolic 
acidosis (pH < 7.2) and hypocalcaemia (< 1 
mmol/L); they must be avoided to decrease the risk 
of TIC.
3.1. Hypothermia
Upon arrival at the incident, since clinical evaluation 
is of the utmost importance, undressing the victim 
is a priority. However, this should be accompanied 
by the use of blankets or fluid heaters to maintain 
normal body temperature. Maintaining a lower 
temperature of 33-35 °C should be considered in 
patients with isolated traumatic brain injury (TBI) 
once haemorrhaging is controlled. Hypothermia 
reduces platelet and coagulation factor function – 
for example, a drop of 1 °C in body temperature 
leads to a 10% drop in function, enzyme inhibition 
and fibrinolysis.49 
Avoid potential heat loss and warm the patient 
(Grade 1C) except in cases of isolated TBI (Grade 
2C)49
3.2. Metabolic acidosis
Metabolic acidosis is often seen in trauma patients 
subjected to massive blood transfusions. There are 
two origins of this condition: lactate production 
from hypoperfused tissues or excessive chloride 
administration through the saline drip. At a pH < 7.4, 
various coagulation abnormalities are encountered, 
such as inhibition of thrombin generation and 
increase of degradation of fibrinogen.50 High 
concentrations of lactate in the venous or arterial 
systems constitute an independent predictor of 
mortality in haemorrhagic trauma.51 However, 
this measure is less reliable in alcohol-associated 
trauma because alcohol itself increases a patient’s 
blood lactate level.52 A base deficit derived from 
arterial blood is an alternative measure for such 
patients and is also correlated with mortality.53
Avoid acidosis, measure serum lactate as a 
predictor of poor prognosis in severely injured 
patient (Grade 1B)49
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traumatic coagulopathy persist despite standard 
attempts to control bleeding and best practice use 
of conventional haemostatic measures (Grade 2C). 
6.1. Packed red blood cells
A preliminary question must be answered before 
considering a transfusion of RBC: what haemoglobin 
(Hb) concentration is needed to ensure adequate 
oxygen delivery to tissues? Since oxygen delivery 
is directly related to Hb concentration, a fall in 
Hb concentration could be responsible for tissue 
hypoxia. Therefore, a transfusion is recommended 
if Hb concentration is < 7g/dl and is probably not 
useful if Hb > 10 g/dl.59 Note that, for severe TBI, 
transfusion thresholds are the same. Regarding 
the haematocrit (Hct), this may be influenced 
by administration of intravenous fluid and RBC, 
acting as confounding factors. Therefore, a patient 
with massive blood loss may have a stable Hct due 
to simultaneous loss of plasma and red blood cells, 
while decreasing serial Hct measurements may 
reflect ongoing bleeding.
A target Hb concentration between 7 to 9 g/dl is 
recommended (Grade 1 C). A single Hct is not 
recommended as an isolated laboratory marker of 
bleeding (Grade 1B)49
6.2. Fresh frozen plasma
An FFP plasma unit contains about 70% of the level 
of all normal clotting factors, including fibrinogen. 
One unit of FFP contains, on average, 0.4 to 0.5 
g of fibrinogen. In Belgium, plasma only exists in 
the thawed form. As with other blood components, 
transfusion of plasma is not free from risk of 
worsening post-injury multiple organ failure, acute 
respiratory distress syndrome or infections. Data 
from war zones have demonstrated that a plasma 
to RBC ratio of at least 1:1 decreases the number 
of deaths from haemorrhaging and improves rates 
of survival to hospital discharge.60-62 This positive 
effect of FFP:RBC ≥ 1:1 is not observed among 
survivors after 24 hours.63 This trend combines with 
data from Holcomb et al. (the PROPPR randomized 
clinical trial), which compared a ratio of plasma to 
platelets (1 pool of 6U, on average) to RBC of 1:1:1 
and 1:1:2, in patients with severe trauma and major 
bleeding. They found that, whatever the ratio, there 
was no difference in mortality at either 24 hours 
or 30 days. More patients from the 1:1:1 ratio 
and degree of substitution, as compared to more 
recent HES solutions, accumulate faster and may 
cause renal dysfunction.57 Only 6% HES 130/0.4 
infusion should be used. However, the appropriate 
dosage of these products is as yet unclear. A patient’s 
renal function must be monitored following HES 
infusion.58 
These infusions are safe but do not appear to 
improve survival or neurological outcome. If 
target arterial pressure is not achieved with fluid 
replacement therapy, vasopressors should be 
considered. A targeted systolic blood pressure 
of 80 to 90 mmHg, or ≥ 80 mmHg in the case 
of associated TBI, is recommended until major 
bleeding is controlled. The patient must have a 
large bore intravenous catheter (peripheral or 
central) inserted to transfuse large volumes of fluid 
as quickly as possible. If vascular access is difficult 
an intraosseous infusion should be considered.
Crystalloids are recommended to treat hypotensive 
bleeding trauma patients (Grade 1B). If colloids 
are used, dosage should be within the prescribed 
limits (Grade 1B)49
6. Blood components and plasma-derived 
products
Clinicians must decide when to infuse blood 
products. In Belgium in 2015, available blood 
component products approved by the National 
Institute for Public Sickness Insurance and 
Disability (INAMI/RIZIV) included: packed red 
blood cell (RBC) concentrates: €117.1; platelets: 
€430.4 for a minimum of 4x1011 platelets; fresh 
frozen plasma (FFP): €91.0. Prothrombin complex 
concentrates (PCC), such as PPSB® (€274) or 
fibrinogen (€419), are approved by INAMI/
RIZIV only for specific clinical situations, such 
as treatment of vitamin K antagonist overdose or 
congenital hypofibrinogenaemia, respectively, but 
not in the context of TIC, except for patients taking 
an oral anticoagulant and requiring emergency 
surgery. Activated coagulation factors, such as 
Novoseven®, is reimbursed (50000 UI: €592) in 
patients with congenital deficiencies (haemophilia 
A with FVIIIC inhibitors, congenital deficiency in 
FVII or Glanzmann thrombasthaenia) but not in 
acute trauma. rFVIIa is not a first-line treatment 
for bleeding. We suggest that the use of rFVIIa 
should be considered if major bleeding and 
06-mullier.indd   72 4/11/16   17:09
Facing coagulation disorders after trauma 73
of infectious diseases (including prions) and 
allergic reactions.70 Finally, it should be noted 
that, in Belgium, the use of pathogen inactivation 
methods to decrease the risk of infectious disease 
transmission is mandatory for all plasma use (blood 
components and drugs and platelet concentrates).
7. Special populations: patients taking 
antithrombotic drugs
Given the ageing population, growing numbers 
of patients are taking antithrombotic drugs 
(antiplatelet agents, vitamin K-dependent and 
direct oral anticoagulants: DOAC). When a medical 
history cannot be taken (e.g., for an intubated or 
unconscious patient), the presence of antithrombotic 
agents cannot be assessed from routine laboratory 
data, especially in the case of antiplatelet agents 
and apixaban. 
7.1. Antiplatelet agents
In patients with massive bleeds, platelet transfusion 
is indicated even at high platelet counts.71 
Ticagrelor (Brilique®, AstraZeneca) binds 
reversibly and selectively to the P2Y12 receptor. 
Circulating ticagrelor and its active metabolite are 
likely to inhibit transfused platelets. Case reports 
have demonstrated the ineffectiveness of platelet 
transfusion in the presence of ticagrelor.72 For 
patients taking acetylsalicylic acid, desmopressin 
(0.3 µg/kg) is indicated; for all other patients, 
there is no indication for routine administration of 
desmopressin in massive bleeding due to trauma.50 
Administration of platelets is indicated for patients 
with massive bleeding or TBI who have received 
antiplatelet agents (Grade 2C)49
7.2. Vitamin k-dependent oral anticoagulants
For patients treated with a vitamin K-dependent 
oral anticoagulant, PCC is used if a rapid reversal 
is indicated. This indication must be weighed 
against the risk of thrombosis. The dosage should 
be determined according to the manufacturer’s 
instructions, but is usually around 50 U/kg of body 
weight.
PCCs are used for emergency reversal of vitamin 
K-dependent oral anticoagulants (Grade 1B)49
group reached haemostasis and fewer died from 
exsanguination by 24 hours.64 The aim is to reflect, 
as far as possible, the constitution of whole blood. 
Unavailability of sufficient universal donor (AB) 
plasma may be a clinical challenge when treating 
massively bleeding trauma patients. Male blood 
group A low-titer B has been used as universal donor 
plasma in the early phases of trauma resuscitation 
without evidence of haemolysis or other reactions.65 
In cases of massive bleeding, an FFP:RBC ratio of 
at least 1:2 is recommended (Grade 2C)49
6.3. Fibrinogen
This is the first blood component that reaches a 
critical level during blood loss replacement by 
plasma-poor red cell concentrates.66 The decrease 
in fibrinogen plasma concentration quantified 
by thromboelastography (TEG) or rotational 
thromboelastometry (ROTEM, TEM International 
GmBH, Munich, Germany) measurements 
provides predictive values for massive transfusions 
in trauma patients.67 However, there have not yet 
been enough prospective clinical trials to assess the 
necessity of using a source of additional fibrinogen 
in the management of bleeding trauma patients.68,69
We recommend fibrinogen supplementation if 
significant bleeding is accompanied by thrombo-
elastometric signs of deficit or a plasma level < 1.5 
to 2g/l (Grade 1C): the initial dose is 3 to 4 g 
(Grade 2C)49
6.4. Platelets
The place of platelets in TIC has not been clearly 
shown and is controversial. The threshold for 
transfusion is also a matter for debate, ranging 
from 50,000 to 75,000/µl. A target platelet count 
above 100,000/µl should be considered in patients 
with ongoing bleeding and/or with a TBI. A dose of 
between four and eight platelet units increases the 
platelet count by 30,000 to 50,000/µl.
Platelet count should be maintained > 50,000/
µl (Grade 1C) or > 100,000/µl in patients with 
ongoing bleeding and/or TBI49
As with all blood products, transfusion carries 
risks of circulatory overload, ABO incompatibility 
(usually resulting from human error), transmission 
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and an oxygenator. The return is provided by an 
outflow cannula placed in the superior vena cava 
or pushed from the other femoral vein into the right 
atrium. Cannulas can be inserted using surgical or 
percutaneous approaches.79
- Arteriovenous (AV) ECMO is preferred if 
the heart must be supported (e.g., cardiopulmonary 
failure in a drowned person with hypothermia or 
cardiac contusion) regardless of any lung damage. 
In this configuration, AV-ECMO also provides 
blood flow in place of the heart. The inflow system is 
the same as for VV-ECMO, but the outflow system 
is provided by a cannula placed in the ascending 
aorta, from a femoral or subclavian artery. 
ECMO circuits are supplied with blood, colloids 
or crystalloids. The main potential limit regarding 
their use for trauma patients is the requirement for 
heparinization. Moreover, such systems require 
a dedicated perfusion team which may not be 
available in all settings. 
Part III: Practical implications of traumatic 
coagulopathy on surgical management
1. Introduction
Post-traumatic or hazard-induced coagulopathy 
must be aggressively corrected in all patients and 
especially in those with severe head or neck injuries. 
Trauma resuscitation for severely injured patients 
has undergone a paradigm shift in the last decade, 
with many centres switching from crystalloid-
based to blood product-based resuscitation. 
Damage control resuscitation (DCR)80 includes 
early blood product transfusion, immediate arrest 
and/or temporization of ongoing haemorrhage 
(i.e., temporary intravascular shunts and/or balloon 
tamponades), permissive hypotension, restoration 
of blood volume and physiological/haematological 
stability,81 and coagulopathy correction. DCR is 
strongly recommended if available on-site or at the 
first tactical care level.82
Some essential lessons can be learned from 
military medicine, where polytrauma is the 
predominant form of battlefield injury and where 
catastrophic blood loss often leads to death. Neck 
wounds commonly cause life-threatening blood 
loss. Exsanguinating haemorrhage accounts for 33-
40% of all trauma-associated deaths, approximately 
half of which occur before the patient reaches the 
7.3. Direct oral anticoagulants
For patients treated with direct oral anticoagulants 
(dabigatran: anti-IIa/rivaroxaban, apixaban and 
edoxaban: anti-Xa), in cases of life-threatening 
bleeding, PCC of 25 to 50 U/kg can be used.73 
Haemodialysis may be a suitable approach for 
dabigatran due to its renal elimination and low 
protein binding. Nevertheless, the most important 
advance in this field is the availability of specific 
antidotes. Andexanet and ciraparantag are being 
studied as antidotes for anti-Xa. However, it is not 
yet known if these antidotes improve outcomes in 
patients with massive bleeding. For dabigatran, a 
humanized monoclonal antibody antigen-binding 
fragment, idarucizumab (Praxbind®), was approved 
by the US Food and Drug Administration (FDA) 
in October 201574 and the European Medicines 
Agency (EMA) in November 2015.
For DOACs, PCC (25-50 U/kg) can be used 
(Grade 2C), antidotes are under evaluation for 
FXa inhibitors and Praxbind® is authorized for 
dabigatran.49
8. Special situation: extracorporeal membrane 
oxygenation (ecMo) and trauma 
Thoracic injuries occur in about 50% of patients 
with multiple trauma.75 These may cause acute lung 
failure (ALF), which can rapidly lead to death due 
to life-threatening impairment in gas exchange 
(hypoxia, hypercapnia and respiratory acidosis). 
If conventional mechanical ventilation strategies 
fail, ECMO can be considered to support tissue 
oxygenation.76 Apart from ALF – and if anatomical 
sites of bleeding are controlled – another indication 
for ECMO in trauma patients is tracheobronchial 
injury.77 The type of ECMO used should be dictated 
by the affected organ: 
- Venovenous (VV) ECMO can be used as 
lung support in trauma patients with chest injuries 
without cardiac dysfunction. For example, the 
following situations may justify a VV-ECMO: 
pulmonary contusions after blunt trauma leading 
to alveolar haemorrhage and parenchymal 
destruction,78 air leak in the tracheobronchial tree 
or compromised airway patency and secondary 
pneumonia. A VV-ECMO circuit is composed of 
an inflow cannula placed in the mid inferior vena 
cava via a femoral vein, and connected to a pump 
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of bleeding trauma patients. Massive bleeding in 
trauma patients was defined as the loss of total 
blood volume within 24 hours or the loss of 50% of 
blood volume within three hours.97 It recommends 
that the time between injury and operation should 
be minimized for patients in need of urgent surgical 
bleeding control and that patients presenting with 
haemorrhagic shock and an identified source 
of bleeding should undergo immediate surgical 
bleeding control if initial resuscitation measures are 
not successful. Finally, adopting a DCS approach 
is considered essential for severely injured patients 
(Figure 2).98-100
DCS is the most technically demanding and 
challenging surgery a trauma surgeon can perform.101 
Such techniques are used to manage critically 
ill patients. The emphasis is on restoring normal 
physiology to prevent the “lethal triad” (metabolic 
acidosis, hypothermia and coagulopathy) rather 
than correcting anatomy.102,103
DCS is indicated when a person sustains a 
severe injury that impairs their ability to maintain 
homeostasis due to severe haemorrhage.104 As 
with DCR, the principles of DCS are control of 
hospital.83-86 However, another major cause of death 
in head and face injuries is airway compromise.87,88
Although the head and neck region accounts for 
only 12% of total body surface area, head and neck 
injuries are seen in over 20% of battlefield casualties 
in 21st century conflicts.89,90 By comparison, in 
the 20th century approximately 16% of battlefield 
injuries involved the head and neck regions.91 This is 
most likely due to a reduction in thoracoabdominal 
injuries due to the effectiveness of modern body 
armour, combined with the increased incidence of 
improvised explosive devices.92
For these reasons, the concepts of DCR and 
damage control surgery (DCS)93-95 have been 
developed and applied to all severely injured oral 
and maxillofacial surgical patients.96
2. Surgery to control haemorrhage
2.1. Introducing DCS 
In 2007, the multidisciplinary Task Force for 
Advanced Bleeding Care in Trauma published 
evidence-based recommendations and flow charts 
covering many aspects of the acute management 
Figure 2
Medical treatment of traumatic coagulopathy. Adapted from Spahn DR et al.49 
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2.3.1. Phase 0 (Ground 0): prehospital and early 
resuscitation
The emphasis of phase 0 is the early recognition 
of patients who are at risk of developing the 
“lethal triad” and those for whom damage control 
techniques may be indicated.
The management steps of phase 0 are the 
following: stop bleeding using tourniquets or 
direct pressure (if the patient has noncompressible 
bleeding, practice permissive hypotension),115 
stabilize following the ABCDE (Airways, 
Breathing, Circulation, Disability and Exposure) 
sequence, rapidly transfer to the medical treatment 
facility with initiation of DCR, prevent the “lethal 
triad” and, finally, rapidly transfer to the operating 
room.
haemorrhage, prevention of contamination and 
protection from further injury.105 The physiological 
impact of surgery is limited by carrying out the 
minimum amount of surgery in the shortest time 
necessary to stabilize the patient, prevent infection 
and avoid the “lethal triad”.
While it may be tempting to combine DCS 
with a definitive, corrective operation, this should 
be avoided as patients may yet succumb to the 
physiopathological effects of the injury, despite 
anatomical correction.
2.2. Indications for DCS (Table 1)
The earlier DCS is applied in at-risk patients,106 
the better the outcomes.107-109 Patients who died in 
hospital during the DCR period were more likely 
to be severely injured and to have had severe brain 
injury, consistent with a decrease in deaths among 
potentially salvageable patients.110
Another complementary consideration could be 
added to the DCS paradigm:
the requirement to take into account the ability 
to control haemorrhage – for example, in cases of 
severe abdominal compartment syndrome,111 liver 
injury112 or associated injuries.113,114
2.3. Phases of DCS (Figure 3)
Tactical Combat Casualty Care for Medical 
Personnel (TCCC) guidelines are designed to direct 
basic management of care under fire or in hostile 
environments. The phases of TCCC are: (1) Care 
Under Fire (or in an unstable environment), (2) 
Tactical Field Care and (3) Tactical Evacuation 
Care, mainly determined according to distinct 
hazard zones (hot, warm or cold) (cfr. chapter on 
prehospital interventions).
Patient Symptoms Severity stage
Is presenting with or is at risk for 
developing
Multiple life-threatening injuries
Acidosis pH < 7.25
Hypothermia Temperature < 34 °C
Shock45 on presentation
Combined hollow viscous and vascular or 
vascularized organ injury
Coagulopathy INR > 1.4
Mass casualty situation
Table 1
Indications for damage control surgery
Figure 3
Damage control surgery paradigm. In contrast with previous 
views regarding trauma management, DCS is characterized by 
sequences of abbreviated surgery followed by resuscitation in 
an ICU with subsequent revision or repair until restoration of a 
normal physiology is achieved.
(ER): Emergency Room; (OR): Operating Room; (ICU): 
Intensive Care Unit
06-mullier.indd   76 4/11/16   17:09
Facing coagulation disorders after trauma 77
The principles of management include early 
tracheotomy (cfr. chapter on complex intubation, 
cricothyroidotomy and tracheotomy), vigorous 
replacement of blood loss and correction of 
coagulopathy, nasal packing, neck exploration 
and management of carotid injury, early generous 
decompressive craniotomy, intracranial haematoma 
evacuation, removal of accessible fragments and 
debridement of devitalized cerebral tissue, external 
ventricle drain, duraplasty and use of broad-
spectrum antibiotics.  
The neurosurgical procedures required for these 
injuries are generally more extensive and aggressive 
than those that have been described for penetrating 
brain injuries in the literature from previous wars. 
A CT scan (if available) is invaluable for planning 
the extent of neurosurgery and CT angiography 
is useful when cervical vascular injuries are 
suspected. The timing and extent of neurosurgery 
and maxillofacial surgery must be balanced against 
the relative priorities of other injuries and the state 
of physiological stabilization. Repair of ocular 
injury or eye removal is often deferred.118
2.5. Particular issues in generic DCS relevant 
for ent specialists  
2.5.1. Thoracic injuries 
The goal of abbreviated thoracotomy is to stop 
bleeding and restore a survivable physiology; 
contamination is usually not a problem. Tracheal 
injury can be temporized with airway control 
placed through the site of injury (mask or tube) (cfr. 
chapter on complex intubation, cricothyroidotomy 
and tracheotomy). When dealing with oesophageal 
injury, nasogastric tube diversion and wide 
drainage, without definitive organ repair, are the 
best initial courses of action.119
2.5.2. Specific DCS considerations in head and 
neck injuries
(For more detail, please consult the chapter on neck 
injuries.)
Maxillofacial DCS is restricted to tracheotomy, 
arrest of haemorrhage, initial wound debridement, 
reduction and immobilization of fractures and sight-
saving procedures, such as lateral canthotomy.120 
Vascular injury is seen in 20% of cases involving 
penetrating neck trauma and exsanguination is the 
primary cause of death.
2.3.2. Phase 1: primary DCS 
Primary DCS aims to control haemorrhage and 
contamination, determine the extent of injury, apply 
therapeutic packing and, if necessary, perform 
temporary abdominal closure.
2.3.3. Phase 2: critical care
Physiological support of the post-operative DCS 
patient is paramount to survival. This phase 
includes: core rewarming (by means of warmed 
resuscitative fluids, blankets, ventilator air and 
environment), reversal of coagulopathy using 
coagulation factor replacement, ventilation support 
(preferring ARDSNet116 low tidal volume to avoid 
barotrauma) and, finally, injury identification.
2.3.4. Phase 3: planned re-operation
Packing should generally be left in place until 
the patient’s haemodynamic profile is stabilized 
and all major sites of haemorrhage have had time 
to clot. When removed, packing should be taken 
out slowly with plans for vascular control. Re-
operation should be scheduled when the probability 
of achieving definitive organ repair and complete 
fascia closure is highest, although an estimation 
that the fascia cannot be closed should not preclude 
initial re-exploration(s). Re-exploration must 
occur after correction of hypotension, acidosis, 
hypothermia and coagulopathy. It typically occurs 
24-48 hours following the initial operation. Timing 
can, however, be dictated by other pressing clinical 
concerns, such as cardiac failure, limb ischaemia 
and suboptimal control of spillage at primary 
operation.
2.3.5. Unplanned re-exploration
Emergent, unplanned re-exploration should be 
considered in any patient who remains unstable, 
persistently coagulopathic or acidotic despite 
continued resuscitation and full cardiopulmonary 
support.
2.4. Principles of management for head and 
neck surgery117
Surgical judgement is required to determine the 
amount of soft tissue and bone debridement that 
is initially required to adequately clean tissues 
and prevent infection, and which early definitive 
treatments can be performed to provide the best 
possible final form and function.
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expanding haematoma, pulsatile haemorrhage, 
palpable thrill or audible bruit, and signs of 
neurovascular compromise.
2.5.3. Example of bomb blasts
Bomb blasts cause combinations of blast injury, 
The neck is traditionally divided into three 
zones to aid decision-making and management 
(Figure 4). Zone 2 neck injuries involving hard signs 
of vascular injury require immediate exploration, 
eventually supported by angiography.121 These hard 
signs include uncontrollable haemorrhage, rapidly 
Does not affect Occasionally affects Frequently affects
- Prophylactic dose of heparin, LMWH 
or fondaparinux
- Osler-Weber-Rendu syndrome 
(hereditary haemorrhagic
telangiectasia)
- Mild thrombocytopaenia (e.g., > 
60,000/ml)
- Aspirin or NSAID administration
- Poor metabolic/nutrition states
- Moderate thrombocytopaenia (30,000-
60,000/ml)
- Platelet defects, especially with 
concomitant aspirin or NSAID 
administration
- Factor VIII or IX < 30% of normal 
levels
- Fibrinogen < 60 mg/dl
- Severe thrombocytopaenia (< 30,000/
ml)
- Multiorgan failure
Table 2
Factors capable of influencing peroperative and post-operative bleeding
Peroperative haemorrhage Early post-operative (days zero to three)
Delayed post-operative bleeding (days 
three to seven)
- Structural/technical defects
- Disseminated intravascular coagulation
- Anticoagulant overdosage
- Hyperfibrinolysis
- Structural/technical defects
- Thrombocytopaenia
- Qualitative platelet disorders
- Mild/moderate hereditary coagulation 
disorder
- Thrombocytopaenia
- Aspirin or NSAID administration
- Vitamin K deficiency
- Multiorgan failure
- Poor wound healing (often with dehis-
cence) from chronic liver disease
Table 3
Major causes of peroperative or post-operative haemorrhage
Figure 4
Neck zones as considered in DSC
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and systematically all wounds and tissue damage 
to avoid, as far as possible, all immediate or post-
operative contamination. Contamination control 
also proceeds as injuries are encountered, utilizing 
clamps, primary repair or resection without 
reanastomosis.
3.2.2. Late-onset complications: wound healing
Wound healing is a highly coordinated process 
involving clot formation, inflammatory reaction, 
immune response and, finally, tissue remodelling 
and maturation. All interfering phenomena, such 
as coagulation disorders or locoregional infections, 
can lead to poor healing with extensive fibrotic 
fields inside the tissue parenchyma.123,124
4. conclusions and take home messages for 
ent specialists
1) Consider DCS in patients who present with, or 
are at risk of developing, the “lethal triad”, multiple 
life-threatening injuries, shock125 or in mass casualty 
situations.
2) Injuries to zone 2 of the neck require 
emergency surgical haemorrhage control.
3) Besides haemorrhage control, DCS also aims 
to evaluate the extent of tissue injuries and to 
control haemorrhage and infection.
Part IV: Interest of laboratory tests 
Point-of-care assays, such as thromboelastometry 
(ROTEM), are often used to guide administration of 
fibrinogen and prothrombin complex concentrates126 
in TIC.
However, there is currently no evidence of the 
added value of such approaches in the management 
of traumatic coagulopathy.127,128 For example, 
fibrinolytic activation (FA) occurs in the majority of 
trauma patients and the magnitude of FA correlates 
with poor clinical outcomes. This is not detected 
by conventional ROTEM, which is an insensitive 
measure of endogenous fibrinolytic activity.129
In addition, the use of laboratory assays 
complicates patient management and prevents early 
treatment. There is no proof that peripheral blood 
reflects what is happening at the site of bleeding. 
Finally, a multicentre study showed very high 
variability between centres for ROTEM analysis, 
with a potential impact on patient management 
decisions. This illustrates the need for external 
multiple penetrating injuries and burns. The pattern 
of injury to the head and neck includes intracranial 
haemorrhage, brain swelling with multiple 
intracranial metal and bone fragments, cervical 
and facial vascular injury, pharyngolaryngeal 
injury, acute airway compromise, facial and scalp 
burns, large scalp defects and extensive skull base 
fractures.  
3. Surgical issues due to coagulation impair-
ments
3.1. Peri-operative risks
The direct consequence of post-traumatic or post-
hazard coagulopathy is a higher risk of massive 
and ubiquitous peroperative haemorrhage. Some 
metabolic factors have been recognized as capable 
of affecting the peroperative or post-operative 
coagulation function (cfr. Table 2).101 On the other 
hand, the delay of post-operative bleeding can be 
suggestive of underlying coagulation disorders (cfr. 
Table 3).101
Ligation, shunting or repair of injured vessels can 
control haemorrhage from visible blood vessels as 
they are encountered. The initial goal is control of 
the haemorrhage, rather than maintenance of blood 
flow. For patients in extremis, clamping or shunting 
of major vessels is recommended over repair. 
When necessary, fasciotomy should be performed. 
Additional methods of haemorrhage control can 
include balloon catheter tamponade of vascular or 
solid viscous injuries.
3.2. Post-operative risks
3.2.1. Early-onset complications
Considering that sometimes casualty evacuation 
is difficult, or that a surge of casualties to the 
tactical field care centre can occur, the risk of 
wound infection is substantial. TCCC procedures, 
described in the chapter dedicated to prehospital 
interventions, recommend systematic use of 
antibiotics for all open wounds on arrival at the 
tactical field care centre. If oral administration 
is possible, Moxifloxacin 400 mg PO once a 
day should be prescribed. In case of shock or 
unconsciousness, high doses of cephalosporins or 
beta-lactam antibiotics should be administered via 
IV or IM.122 DCS consolidates the pharmacological 
effects of such interventions, controlling locally 
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